A beneficial impact of antibiotic therapy on resolution of otitis media with effusion (OME) in children was first demonstrated through systematic review of randomized controlled trials (RCTs) in 1992. 1 Despite this finding, concerns of drug-induced bacterial resistance and the apparent short-term nature of the benefit obtained led to a recommendation against routine treatment of OME in children with antibiotics, as monotherapy or in combination with a corticosteroid. 2 Since this recommendation, however, additional RCTs have been published, and the method for evidence synthesis has matured. The high prevalence of OME mandates that all clinicians who manage children base treatment decisions on high-quality evidence with the lowest risk of bias, a task that is facilitated by the information in this review.
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Background
Otitis media with effusion (OME) is characterized by an accumulation of fluid in the middle ear behind an intact tympanic membrane, without the symptoms or signs of acute infection. In approximately one in three children with OME, however, a bacterial pathogen is identified in the middle ear fluid. In most cases, OME causes mild hearing impairment of short duration. When experienced in early life and when episodes of (bilateral) OME persist or recur, the associated hearing loss may be significant and have a negative impact on speech development and behavior. Since most cases of OME will resolve spontaneously, only children with persistent middle ear effusion and associated hearing loss potentially require treatment. Previous Cochrane reviews have focused on the effectiveness of ventilation tube insertion, adenoidectomy, autoinflation, antihistamines, decongestants, and oral and topical intranasal steroids in OME. This review focuses on the effectiveness of antibiotics in children with OME.
Objectives
To assess the effects of antibiotics in children up to 18 years with OME.
Search Methods
We searched the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL); PubMed; EMBASE; CINAHL; Web of Science; BIOSIS Previews; Cambridge Scientific Abstracts; ICTRP and additional sources for published and unpublished trials. The date of the search was 22 February 2012.
Selection Criteria
Randomized controlled trials comparing oral antibiotics with placebo, no treatment or therapy of unproven effectiveness. Our primary outcome was complete resolution of OME at two to three months. Secondary outcomes included resolution of OME at other time points, hearing, language and speech, ventilation tube insertion and adverse effects.
Data Collection and Analysis
Two authors independently extracted data using standardized data extraction forms and assessed the quality of the included studies using the Cochrane ''Risk of bias'' tool. We presented dichotomous results as risk differences as well as risk ratios, with their 95% confidence intervals. If heterogeneity was greater than 75% we did not pool data.
Main Results
We included 23 studies (3027 children) covering a range of antibiotics, participants, outcome measures, and time points of evaluation. Overall, we assessed the studies as generally being at low risk of bias.
Our primary outcome was complete resolution of OME at two to three months. The differences (improvement) in the proportion of children having such resolution (risk difference (RD)) in the five individual included studies ranged from 1% (RD 0.01, 95% CI 20.11 to 0.12; not significant) to 45% (RD 0.45, 95% CI 0.25 to 0.65). Results from these studies could not be pooled due to clinical and statistical heterogeneity.
Pooled analysis of data for complete resolution at more than six months was possible, with an increase in resolution of 13% (RD 0.13, 95% CI 0.06 to 0.19).
Pooled analysis was also possible for complete resolution at the end of treatment, with the following increases in resolution rates: 17% (RD 0.17, 95% CI 0.09 to 0.24) for treatment for 10 days to two weeks, 34% (RD 0.34, 95% CI 0.19 to 0.50) for treatment for four weeks, 32% (RD 0.32, 95% CI 0.17 to 0.47) for treatment for three months, and 14% (RD 0.14, 95% CI 0.03 to 0.24) for treatment continuously for at least six months.
We were unable to find evidence of a substantial improvement in hearing as a result of the use of antibiotics for otitis media with effusion; nor did we find an effect on the rate of ventilation tube insertion. We did not identify any trials that looked at speech, language, and cognitive development or quality of life.
Data on the adverse effects of antibiotic treatment reported in six studies could not be pooled due to high heterogeneity. Increases in the occurrence of adverse events varied from 3% (RD 0.03, 95% CI 20.01 to 0.07; not significant) to 33% (RD 0.33, 95% CI 0.22 to 0.44) in the individual studies.
Authors' Conclusions
The results of our review do not support the routine use of antibiotics for children up to 18 years with otitis media with effusion. The largest effects of antibiotics were seen in children treated continuously for four weeks and three months. Even when clear and relevant benefits of antibiotics have been demonstrated, these must be balanced against the potential adverse effects when making treatment decisions. Immediate adverse effects of antibiotics are common and the emergence of bacterial resistance has been causally linked to the widespread use of antibiotics for common conditions such as otitis media.
Comments on Cochrane Review Comments by Darrow
The rationale for treating OME with antibiotics is that it may be preceded by bacterial infection, and bacterial pathogens are cultured in approximately one-third of middle ear effusions (MEEs). 4 Furthermore, bacterial DNA and messenger RNA have been detected by polymerase chain reaction in MEEs, 5 and bacterial biofilms and live bacteria have also been demonstrated with high frequency. 6, 7 In their review of 23 studies involving 3027 children, van Zon and colleagues 3 noted that choice of antibiotic, duration of therapy, outcome measures, and times of assessment varied considerably. Interestingly, they did not discuss the homogeneity of the medical history that preceded enrollment in the included studies, particularly the duration of the presence of fluid. This information would be important since, as the authors themselves observe, newly detected OME (of unknown prior duration) spontaneously resolves within 3 months in only 28% of children, whereas spontaneous resolution of OME following a known episode of acute otitis media (AOM) is around 74%. 8 The authors established a primary outcome measure of complete resolution of OME at 2 to 3 months. Two studies in which antibiotics were given for 2 weeks demonstrated resolution rates of 1% and 30%, whereas 3 studies in which antibiotics were given for 3 months found resolution in 15% to 45%. The reviewers determined that results from the included studies could not be pooled due to heterogeneity. When they were used for 1 or 3 months, antibiotics resulted in 34% and 32% improvements in resolution, respectively, by the end of treatment ( Table 1) .
A recommendation against routinely treating OME with antibiotics, even when most analyses ( Table 1) show a statistically significant benefit, must be based on adverse events, benefits that lack clinical importance, or both. Although 2 included studies demonstrated minimal improvement in mean speech recognition thresholds, effusion-related hearing loss can still be associated with reduced responsiveness in the classroom, elevated television volumes at home, and reduced quality of life. [9] [10] [11] Furthermore, no studies examined tympanic membrane retraction or atrophy, or hearing loss or complications associated with these changes. Finally, the risk of adverse effects such as skin rash, diaper dermatitis, diarrhea, and vomiting was less than 10% in 5 of the 6 included studies. The authors cite studies outside their analysis to establish a higher rate of adverse effects.
Although a conclusion that routine use of antibiotics for treating OME is not justified may be true, it is not entirely supported by this study, which reveals definite improvements in OME resolution with antibiotics while failing to demonstrate a significant risk of adverse effects. In addition, the authors seem to impose their own judgment that resolution of hearing loss due to OME is not an important goal of treatment, while overlooking other potential advantages of OME clearance such as reductions in tympanic membrane sequelae, otalgia, and occurrences of acute otitis media (AOM).
If in fact there is some advantage to using antibiotics for OME with a low risk of relatively mild complications, a brief course of medical therapy is a reasonable alternative to surgery for a child who is struggling at school or developing structural changes in the eardrum. 2 The results may be further improved when antibiotics are given concurrently with corticosteroids. 2 Of course, many children with OME referred for tympanostomy tubes have already been treated with multiple courses of antibiotics; for such children, the risk of adverse effects due to additional antibiotics certainly outweighs the likelihood of improvement with additional therapy, underscoring the importance of determining prior therapy and duration of effusion. Ultimately, the decision to treat OME with antibiotics is made between a family and their physician, based on how the persisting effusion is affecting the family and child and their willingness to accept the risk of adverse effects.
Comments by Schilder
Dr Darrow raises a number of important issues pertinent to this review and to managing OME, in general, and in particular the duration of OME at baseline as a potential predictor of resolution of middle ear fluid. Although resolution rates for OME following an episode of AOM are known to be higher than for newly detected OME, it is largely unknown whether this is also true for newly detected OME of short duration vs persistent OME. Duration of OME at baseline varied highly from ''any'' to more than 3 months across the included trials. For the primary outcome ''complete resolution of OME at two to three months,'' however, 4 of the 5 (n = 439) trials included children with OME persisting for a minimum of 2 or 3 months, and 1 trial included children with OME for more than 1 month. Therefore, we could not study whether the benefits of antibiotics differed in those with OME of short duration or following AOM from those with persistent OME.
I agree with Dr Darrow that the results of most trials included in the review point toward a small to modest beneficial effect of antibiotics on the resolution of OME. This would, at first glance, support the use of antibiotics in OME. However, in clinical practice, it is not the middle ear effusion as such we aim to treat; rather, the aim is to alleviate, or prevent, the associated hearing loss and potential detrimental effects on quality of life and speech and language development. We were unable to find sufficient evidence to support beneficial effects of antibiotics in these domains. As the focus of the trials included in this review was OME, newly detected AOM was reported in only 2 trials (n = 202) in which children received continuous antibiotics or placebo for 6 months. Antibiotic treatment reduced the proportion of children experiencing new AOM episodes by 20% (95% confidence interval, 0.37-0.95; number needed to treat = 5). None of these studies included parental reported adverse effects.
Although this Cochrane view does not support the routine use of antibiotics in children with OME, I do agree that in some children, its benefits, as shown in some of our analyses, may be worth the potential downsides of treatment. In particular, as a possible alternative to tube insertion, a single course of antibiotics may be something the clinician and parent decide to try. We hope this Cochrane Review answers some of the questions around this common condition and at the same time provides a rich source of information for future studies. This Cochrane Corner breaks with the tradition of comments by Mr Martin J. Burton in his role as Coordinating Editor of the Cochrane ENT Disorders Group. Since June 2012, Martin and I have shared this role as joint Coordinating Editors. I feel privileged to join my friends and colleagues in the United States as a contributor to this journal.
Comments by Rosenfeld
Having published the first meta-analysis of antibiotics for OME more than 2 decades ago, 1 I was pleased to note that this new and more rigorous analysis reached the same conclusion: despite a modest impact on effusion resolution, routine antibiotic therapy is unjustified because of potential adverse events. Interest in conducting RCTs of antibiotic efficacy for OME waned substantially after our study appeared in 1992, with only 8 of the 23 articles in the current review published thereafter. Nonetheless, the role of antibiotics in managing OME is still debated, as evidenced by the somewhat contrasting viewpoints offered in this Cochrane Corner.
In pondering the role of medical management, in general, of OME, it helps to recall that otitis media is primarily a eustachian tube problem. In the words of my mentor, Charles Bluestone, a child's eustachian tubes are ''too short, too floppy, too horizontal, and don't work.'' Antibiotics, of course, have no lasting impact on eustachian tube function, and the modest improvements after therapy are often transient, persisting only until the child's next upper respiratory infection, AOM, or reflux of nasopharyngeal secretions into the middle ear. Otitis media remains the ultimate occupational hazard of early childhood, the only real ''cures'' being maturation of the child's eustachian tubes and immune system.
A key role of Cochrane Reviews is to arm clinicians with raw material to facilitate evidence-based health care decisions. This review succeeds admirably in that task, leaving it to clinicians and caregivers to decide if the benefits of antibiotic therapy outweigh the potential adverse events and likelihood of OME relapse. In most cases, I would argue they do not, but sparing and judicious use of antibiotics in children with OME who are symptomatic or become surgical candidates would seem reasonable.
